In the phase I/II ECHO-202/Keynote 037 study, which combined the IDO1 inhibitor epacadostat with pembrolizumab, among 2 patients with HNSCC who were included, one patient had stable disease as best response [154]. Here, IDO1 is linked to head and neck squamous cell carcinoma.